OncRef

Clinical Trial: NCT03309878

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2023-09-21

Study Overview

Brief Summary

This phase I/II trial studies the best dose and side effects of mogamulizumab in combination with pembrolizumab and to see how well they work in treating patients with diffuse large B cell lymphoma that have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as mogamulizumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma

Conditions

Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Intervention / Treatment

  • Biological: Mogamulizumab
  • Biological: Pembrolizumab

Other Study ID Numbers

  • NCI-2017-01865
  • NCI-2017-01865
  • 19-018
  • 10106
  • 10106
  • UM1CA186691

Start Date (Actual)

2018-10-24

Primary Completion Date (Actual)

2021-01-06

Study Completion Date (Actual)

2023-04-11

Enrollment (Actual)

8

Study Type

Interventional

Phase

Phase 1, Phase 2